Canaccord Genuity reaffirmed their buy rating on shares of NuVasive, Inc. (NASDAQ:NUVA) in a report published on Friday. Canaccord Genuity currently has a $80.00 price target on the medical device company’s stock.

A number of other research firms have also recently weighed in on NUVA. Cowen and Company reiterated an outperform rating and set a $90.00 price target (up from $85.00) on shares of NuVasive in a report on Wednesday, June 28th. Robert W. Baird cut NuVasive from an outperform rating to a neutral rating and lowered their price target for the stock from $79.00 to $72.00 in a report on Friday. Royal Bank Of Canada reiterated a buy rating and set a $85.00 price target on shares of NuVasive in a report on Thursday, July 20th. BidaskClub upgraded NuVasive from a hold rating to a buy rating in a report on Wednesday, July 19th. Finally, Piper Jaffray Companies increased their price target on NuVasive from $80.00 to $90.00 and gave the stock an overweight rating in a report on Monday, June 12th. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. NuVasive currently has a consensus rating of Buy and an average price target of $81.36.

Shares of NuVasive (NASDAQ:NUVA) traded down 2.55% during mid-day trading on Friday, reaching $64.11. The company had a trading volume of 754,449 shares. The stock’s 50-day moving average price is $77.23 and its 200 day moving average price is $74.47. NuVasive has a 1-year low of $56.70 and a 1-year high of $81.68. The company has a market capitalization of $3.26 billion, a PE ratio of 100.96 and a beta of 1.08.

NuVasive (NASDAQ:NUVA) last issued its earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. The company had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 EPS. Equities analysts expect that NuVasive will post $2.01 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/nuvasive-inc-nasdaqnuva-receives-buy-rating-from-canaccord-genuity/1465823.html.

Large investors have recently bought and sold shares of the stock. Keybank National Association OH raised its stake in NuVasive by 0.7% in the first quarter. Keybank National Association OH now owns 12,667 shares of the medical device company’s stock worth $946,000 after buying an additional 86 shares in the last quarter. Columbus Circle Investors raised its stake in NuVasive by 7.9% in the first quarter. Columbus Circle Investors now owns 745,483 shares of the medical device company’s stock worth $55,673,000 after buying an additional 54,291 shares in the last quarter. Stephens Investment Management Group LLC raised its stake in NuVasive by 7.5% in the first quarter. Stephens Investment Management Group LLC now owns 685,623 shares of the medical device company’s stock worth $51,202,000 after buying an additional 47,707 shares in the last quarter. Pacer Advisors Inc. raised its stake in NuVasive by 22.0% in the first quarter. Pacer Advisors Inc. now owns 5,244 shares of the medical device company’s stock worth $392,000 after buying an additional 945 shares in the last quarter. Finally, OppenheimerFunds Inc. raised its stake in NuVasive by 55.8% in the first quarter. OppenheimerFunds Inc. now owns 1,210,999 shares of the medical device company’s stock worth $90,438,000 after buying an additional 433,506 shares in the last quarter.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.